查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2016937

尿液检查市场：依产品、应用和最终用途划分－2026-2032年全球市场预测

Urinalysis Market by Product, Application, End Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年尿液检查市场价值 42.6 亿美元，预计到 2026 年将成长至 45.4 亿美元，复合年增长率为 6.85%，到 2032 年将达到 67.8 亿美元。

主要市场统计数据
基准年 2025 42.6亿美元
预计年份：2026年 45.4亿美元
预测年份 2032 67.8亿美元
复合年增长率 (%) 6.85%

详细介绍诊断技术创新、临床重点和数据整合如何重新定义尿液检查在所有医疗保健环境中的作用。

尿液检查仍是基层医疗、医院检查室和分散式检查环境中至关重要的诊断工具，既可作为快速筛检方法，也可作为临床医生进行长期监测的手段。在自动化、数位影像处理、试剂化学和互通性等创新技术的推动下，该领域正在超越其传统角色。这些进步有望提高诊断准确性，同时缩短结果获取时间。因此，检测途径也从社区医疗机构使用的照护现场试纸，到整合到高通量检查室工作流程中的全自动分析仪，涵盖了广泛的临床应用场景。

自动化、数位分析、分散式检查和供应链弹性的整合如何重新定义诊断工作流程和病患照护路径。

近年来，尿液检查的实施方式、结果解读方式以及与诊疗流程的整合方式都发生了变革性变化。自动化技术超越了简单的机械化，融合了先进的影像分析和模式识别技术，使检查室能够以更高的一致性处理更多检体。同时，软体主导的解决方案透过标记异常结果和减少人工核查的工作量来优化解读流程，从而提高检查室的处理能力并增强报告的一致性。

评估 2025 年价格调整如何重塑耗材和诊断设备的采购趋势、筹资策略和成本结构。

2025年关税措施的实施对尿液检查供应链产生了多方面的影响，耗材和设备都发生了显着变化。依赖进口的企业面临试剂、试纸、一次性用品和某些设备零件进口成本的增加，这导致筹资策略和定价模式受到更严格的审查。因此，检查室和医疗机构正在重新评估其整体拥有成本（TCO），不仅包括初始资本投资，还包括持续的耗材成本和服务合约。

细分市场分析揭示了产品、临床应用和最终用途的差异如何影响采购行为、设计重点和临床效用。

对市场细分的详细分析揭示了不同产品、应用和最终用途类别在技术和采用趋势上的差异，这些差异影响着商业性和临床的优先事项。按产品划分，市场分为耗材和仪器。在耗材方面，试纸条、一次性产品和试剂类别的性能和价值提案各不相同，易用性、储存稳定性和批间一致性是影响买家偏好的主要因素。相比之下，仪器则以其自动化程度和分析方法为特征。全自动尿沉渣分析仪和生化尿液分析仪兼具处理能力和标准化功能。前者进一步细分为流式细胞技术和显微镜尿液分析仪，后者则细分为全自动生化尿沉渣分析仪和半全自动尿沉渣分析仪。每种分析仪在灵敏度、运行时间和安装空间方面各有侧重。

本报告说明了各地区的诊断环境，重点介绍了美洲、欧洲、中东和非洲以及亚太地区的实施模式、监管环境和商业性机会。

区域趋势正在影响战略重点，美洲、欧洲、中东和非洲以及亚太地区的部署模式和法规环境差异显着。在美洲，成熟的检查室网络和对价值医疗日益增长的重视推动了对自动化系统的需求，这些系统能够提升处理能力并实现标准化报告。同时，市场参与企业也在探索照护现场(PoC) 解决方案，以扩大其筛检范围。在欧洲、中东和非洲，不同的监管环境和异质的医疗基础设施要求解决方案具有高度的适应性，能够在集中式和分散式环境中运行，互通性和符合区域标准至关重要。

我们分析公司的策略性倡议，揭示产品系列、服务模式和数位伙伴关係关係如何塑造其在诊断领域的竞争优势。

产业相关人员正透过差异化策略来应对不断变化的临床和商业性压力，这些策略着重于产品广度、服务丰富度和数位转型。领先的製造商正在扩展其耗材产品组合以确保持续的收入，同时提升仪器的易用性和自动化程度，从而减轻检查室的整体营运负担。一些公司优先考虑将分析仪器、试剂和服务合约结合的整合解决方案，以确保生命週期价值，并在分散的站点提供可预测的性能。

制定切实可行的策略挑战，以加强供应链韧性，加速自动化应用，并透过整合服务模式扩大经常性收入。

产业领导企业应优先采取一系列切实可行的措施，以最大限度地满足临床需求并降低营运风险。首先，他们应实现供应链多元化，并促进本地化生产和组装，以减少贸易中断的影响并缩短交货时间。同时，应在合约条款中加入可靠性奖励和情境规划，为关键耗材预留库存缓衝。其次，他们应加快对自动化和人工智慧 (AI) 技术的投资，以减少人工审核并提高诊断一致性，从而确保检查室效率的显着提升和临床医生的信心。

采用严谨的混合方法研究途径，结合专家访谈、第二手资料和检验协议，确保研究结果的可靠性和透明度。

本分析采用混合研究方法，将质性专家见解与系统收集的二手资讯和结构化资料检验结合。主要资讯来源包括对实验室负责人、临床病理学家、采购专家和产品开发经理的访谈，旨在了解第一线观点对营运限制、临床优先事项和采购行为的看法。次要资讯来源包括同行评审文献、监管文件、技术白皮书和公开的企业披露信息，旨在提供有关技术趋势和产品特性的背景信息。

简明扼要地总结了决定尿液检查分析诊断领域竞争地位的技术、营运和商业性要求。

简而言之，尿液检查目前正处于转折点，技术创新、临床重点的转变以及采购环境的变化交织在一起，带来了新的营运和商业挑战。自动化和数位化解读提高了检测的准确性和处理能力，而分散化和家庭检测的普及则扩大了依赖尿液检查诊断的临床实践范围。为了因应这些趋势，相关人员需要重新思考产品设计、供应链结构和服务模式，以持续满足临床医生的需求和病患的期望。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：尿液检查市场：依产品划分

  • 消耗品
    • 油尺
    • 一次性产品
    • 试剂
  • 装置
    • 自动尿沉渣分析仪
      • 流式细胞技术尿液分析仪
      • 尿液显微镜分析仪
    • 尿液生化分析仪
      • 自动生化分析仪
      • 半自动尿沉渣分析仪

第九章：尿液检查市场：依应用领域划分

  • 糖尿病
  • 高血压
  • 肾臟疾病
  • 肝病
  • 尿道感染（UTI）筛检

第十章：尿液检查市场：依最终用途划分

  • 临床检查室
  • 居家照护
  • 医院
  • 研究和学术机构

第十一章尿液检查市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章尿液检查市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章尿液检查市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国尿液检查市场

第十五章：中国尿液检查市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Accurex Biomedical Pvt. Ltd.
  • ACON Laboratories, Inc.
  • Analyticon Biotechnogies GmBH
  • ARKRAY Inc.
  • Beckman Coulter, Inc.
  • BIOBASE Group
  • Cardinal Health, Inc.
  • Clarity Diagnostics, LLC
  • Danaher Corporation
  • DIALAB GmbH
  • Dirui Industrial Co. Ltd.
  • Erba Mannheim
  • F. Hoffmann-La Roche Ltd
  • Genuine Biosystem Pvt Ltd.
  • High Technology, Inc.
  • PZ Cormay SA
  • QuidelOrtho Corporation
  • Randox Laboratories Ltd.
  • Siemens Healthineers AG
  • Sysmex Asia Pacific Pte Ltd.
  • Teco Diagnostics
  • Thermo Fisher Scientific Inc.
  • YD Diagnostics
Product Code: MRR-034B5003034D

The Urinalysis Market was valued at USD 4.26 billion in 2025 and is projected to grow to USD 4.54 billion in 2026, with a CAGR of 6.85%, reaching USD 6.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.26 billion
Estimated Year [2026] USD 4.54 billion
Forecast Year [2032] USD 6.78 billion
CAGR (%) 6.85%

An informed introduction to how diagnostic innovations, clinical priorities, and data connectivity are redefining the role of urinalysis across care settings

Urinalysis remains a cornerstone diagnostic tool across primary care, hospital laboratories, and decentralized testing environments, serving clinicians as both a rapid screening mechanism and a longitudinal monitoring instrument. The discipline is evolving beyond its traditional role, propelled by innovations in automation, digital imaging, reagent chemistry, and interoperability that promise to tighten diagnostic accuracy while reducing time-to-result. Consequently, testing pathways now span from point-of-care strips used in community settings to fully automated analyzers integrated into high-throughput laboratory workflows, reflecting a broad continuum of clinical use cases.

In parallel, clinical priorities are shifting toward earlier detection and continuous monitoring of chronic conditions such as diabetes and kidney disease, which places greater emphasis on reliable urine-based biomarkers and standardized reporting. As stakeholders adapt, the interplay between technological maturation, regulatory expectations, and shifting care models is reshaping procurement and service models. Therefore, a strategic view of the landscape must consider not only device capabilities and consumable logistics but also data flows, quality assurance practices, and the emergent demand for patient-centric and remote testing modalities.

How convergence of automation, digital interpretation, decentralized testing, and supply chain resilience is redefining diagnostic workflows and patient pathways

Recent years have brought transformative shifts that are redefining how urinalysis is conducted, interpreted, and integrated into care pathways. Automation technologies are moving beyond mechanization to include advanced image analysis and pattern recognition, enabling laboratories to process higher volumes with improved consistency. Simultaneously, software-driven solutions are enhancing interpretive workflows by flagging anomalous results and reducing manual review burden, which contributes to improved laboratory throughput and more consistent reporting.

Concurrently, there is heightened emphasis on decentralization and patient empowerment. Home-based testing platforms and simplified point-of-care systems are becoming more prevalent, chiefly to support chronic disease management and community screening programs. These platforms are increasingly designed to interoperate with electronic health records and telehealth systems, supporting seamless clinician oversight. Moreover, supply chain resiliency and sustainability considerations are influencing procurement strategies, while regulatory frameworks continue to evolve to accommodate new technologies and ensure reliable performance across diverse settings. Taken together, these shifts are enabling faster clinical decision-making and creating opportunities for novel service models and recurring revenue streams tied to consumables and digital services.

Assessment of how 2025 tariff shifts have reshaped procurement dynamics, sourcing strategies, and cost structures across consumables and diagnostic instruments

The introduction of tariff measures in 2025 has exerted a multifaceted influence on the urinalysis supply chain, touching both consumables and instruments in meaningful ways. Import-dependent operators have experienced elevated landed costs for reagents, dipsticks, disposables, and certain instrument components, which has intensified scrutiny of procurement strategies and pricing models. As a result, laboratories and healthcare providers are reassessing total cost of ownership considerations, factoring in not only initial capital outlays but also recurring consumable expenses and service commitments.

In response to these pressures, manufacturers and distributors have accelerated diversification of their sourcing footprints, pursued local manufacturing partnerships, and explored regional assembly to mitigate exposure to tariff-related volatility. These adjustments are producing longer-term shifts in supplier relationships and inventory policies, as entities emphasize dual sourcing, strategic inventory buffers, and contractual protections. In addition, some stakeholders have prioritized product modularity and design-for-manufacture approaches to reduce reliance on tariff-impacted components. Collectively, these adaptations are reshaping procurement cycles and commercial negotiations while influencing product roadmaps and pricing strategies across the ecosystem.

Segment-level analysis revealing how product, clinical application, and end-use distinctions influence procurement behavior, design priorities, and clinical utility

A granular examination of segmentation reveals differentiated technology and adoption dynamics across product, application, and end-use categories that shape commercial and clinical priorities. Based on Product, the landscape separates into Consumables and Instruments; within Consumables, distinct performance and value propositions emerge across dipsticks, disposables, and reagents where ease of use, shelf stability, and batch-to-batch consistency are primary drivers of buyer preference. In contrast, Instruments are distinguished by their automation level and analytical approach: Automated Urine Sediment Analyzers and Biochemical Urine Analyzers deliver throughput and standardization with the former further bifurcated into flowcytometric urine analyzers and microscopic urine analyzers and the latter into automated biochemical analyzers and semi-automated urine sediment analyzers, each offering a different balance of sensitivity, hands-on time, and laboratory footprint.

Based on Application, testing is organized around clinical priorities such as diabetes, hypertension, kidney disease, liver disease, and UTI screening, with each indication imposing unique requirements for sensitivity, quantitative reporting, and longitudinal comparability. For instance, chronic disease monitoring demands robust reproducibility and integration with longitudinal electronic records, whereas UTI screening emphasizes rapid turnaround and high negative predictive value. Based on End Use, distinct buyer archetypes-clinical laboratories, home care settings, hospitals, and research & academics-exhibit divergent procurement behavior, service expectations, and technical requirements, which in turn inform product design, service models, and commercialization strategies.

Regional diagnostic landscapes explained to highlight adoption patterns, regulatory variation, and commercial opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics are informing strategic priorities, with adoption patterns and regulatory environments varying considerably across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established laboratory networks and a growing emphasis on value-based care are driving demand for automated systems that enable throughput and standardized reporting, while market participants are also exploring point-of-care solutions to expand screening initiatives. In Europe, Middle East & Africa, diverse regulatory landscapes and heterogeneous healthcare infrastructures require adaptable solutions that can operate across centralized and decentralized settings, with an emphasis on interoperability and compliance with regional standards.

Asia-Pacific presents both rapid adoption curves and localized manufacturing strengths, where large population health initiatives and rising investment in diagnostics are accelerating uptake of both automated analyzers and decentralized testing platforms. Meanwhile, countries in the region vary in reimbursement approaches and laboratory capacity, creating opportunities for scalable, cost-efficient solutions. Across regions, supply chain considerations, local regulatory approvals, and strategic partnerships with regional distributors remain critical for successful market entry and sustained growth.

Corporate strategic moves examined to reveal how product portfolios, service models, and digital partnerships are shaping competitive advantage in diagnostics

Industry participants are responding to evolving clinical and commercial pressures through differentiated strategies focused on product breadth, service intensity, and digital enablement. Leading manufacturers are expanding consumable portfolios to capture recurring revenue while concurrently enhancing instrument usability and automation to reduce total operational burden on laboratories. Some firms are prioritizing integrated solutions that combine analyzers, reagents, and service contracts to lock in lifecycle value and to provide predictable performance across decentralized sites.

Additionally, there is a notable trend toward partnering with digital platform providers to enable remote monitoring, predictive maintenance, and streamlined data exchange with electronic medical records. These alliances enhance customer retention and provide new monetizable service layers. Competitive dynamics also favor organizations that invest in regulatory readiness and quality systems, enabling faster approvals in multiple jurisdictions. Finally, nimble entrants often focus on niche segments-such as home testing or specialized sediment analysis-leveraging agility to secure footholds and to commercialize rapidly while larger players pursue scale and integration.

Actionable strategic imperatives to strengthen supply resilience, accelerate automation adoption, and expand recurring revenue through integrated service models

Industry leaders should prioritize a set of pragmatic actions to capitalize on clinical demand and to mitigate operational risk. First, diversify supply chains and pursue regional manufacturing or assembly to reduce exposure to trade disruptions and to shorten delivery lead times. This step should be accompanied by contractual terms that incentivize reliability and by scenario planning that incorporates inventory buffers for critical consumables. Second, accelerate investment in automation and artificial intelligence capabilities that reduce manual review and improve diagnostic consistency, thereby delivering measurable laboratory efficiencies and clinician confidence.

Third, expand offerings for decentralized testing and home care to capture shifting care models, integrating device outputs with clinical workflows and health record systems to ensure clinician oversight and continuity of care. Fourth, design commercial models that balance instrument sales with consumable and service revenue streams to create recurring income and stronger customer relationships. Finally, engage proactively with regulators and payers to demonstrate clinical utility and cost-effectiveness, and to align product development with reimbursement and quality expectations. Implementing these recommendations in a coordinated manner will strengthen resilience and create sustainable differentiation across competitive markets.

Rigorous mixed-methods research approach combining expert interviews, secondary evidence, and validation protocols to ensure robust and transparent findings

The underlying analysis draws on a mixed-methods research approach that triangulates qualitative insights from subject-matter experts with systematically collected secondary information and structured data validation. Primary inputs include interviews with laboratory directors, clinical pathologists, procurement specialists, and product development leaders to capture first-hand perspectives on operational constraints, clinical priorities, and purchasing behavior. Secondary inputs encompass peer-reviewed literature, regulatory documentation, technical white papers, and publicly available company disclosures to contextualize technology trends and product features.

Findings were validated through cross-checking against multiple independent sources and by reconciling divergent viewpoints via expert panels. Segmentation frameworks were applied to ensure consistent classification across product, application, and end-use categories, and sensitivity checks were performed to gauge the robustness of thematic conclusions. Limitations include the variable availability of granular operational metrics across regions and potential biases inherent in stakeholder interviews; these were mitigated through careful respondent selection and methodological transparency. Ethical considerations guided primary research, with informed consent and confidentiality protections for interview participants.

Concise conclusion synthesizing technological, operational, and commercial imperatives that will determine competitive positioning in urinalysis diagnostics

In sum, urinalysis is at an inflection point where technological innovation, evolving clinical priorities, and shifting procurement realities are converging to create new operational and commercial imperatives. Automation and digital interpretation are enhancing accuracy and throughput, while decentralization and home-based testing are broadening the points of care that rely on urine-based diagnostics. These developments demand that stakeholders rethink product design, supply chain architecture, and service models to remain responsive to clinician needs and to patient expectations.

Strategic investments in supply chain diversification, automation, integrated consumable services, and regulatory engagement will be essential to capture emerging opportunities and to protect margins amid cost pressures. By aligning product roadmaps with clinical workflows and by leveraging digital capabilities for data integration and remote support, organizations can both improve clinical outcomes and create sustainable competitive differentiation. The overarching conclusion is that timely, coordinated actions across technology, operations, and commercial functions will determine which organizations lead the next phase of advancement in urinalysis diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Urinalysis Market, by Product

  • 8.1. Consumables
    • 8.1.1. Dipsticks
    • 8.1.2. Disposables
    • 8.1.3. Reagents
  • 8.2. Instruments
    • 8.2.1. Automated Urine Sediment Analyzers
      • 8.2.1.1. Flowcytometric Urine Analyzers
      • 8.2.1.2. Microscopic Urine Analyzers
    • 8.2.2. Biochemical Urine Analyzer
      • 8.2.2.1. Automated Biochemical Analyzers
      • 8.2.2.2. Semi-automated Urine Sediment Analyzers

9. Urinalysis Market, by Application

  • 9.1. Diabetes
  • 9.2. Hypertension
  • 9.3. Kidney Disease
  • 9.4. Liver Disease
  • 9.5. UTI Screening

10. Urinalysis Market, by End Use

  • 10.1. Clinical Laboratories
  • 10.2. Home Care
  • 10.3. Hospitals
  • 10.4. Research & Academics

11. Urinalysis Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Urinalysis Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Urinalysis Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Urinalysis Market

15. China Urinalysis Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Accurex Biomedical Pvt. Ltd.
  • 16.7. ACON Laboratories, Inc.
  • 16.8. Analyticon Biotechnogies GmBH
  • 16.9. ARKRAY Inc.
  • 16.10. Beckman Coulter, Inc.
  • 16.11. BIOBASE Group
  • 16.12. Cardinal Health, Inc.
  • 16.13. Clarity Diagnostics, LLC
  • 16.14. Danaher Corporation
  • 16.15. DIALAB GmbH
  • 16.16. Dirui Industrial Co. Ltd.
  • 16.17. Erba Mannheim
  • 16.18. F. Hoffmann-La Roche Ltd
  • 16.19. Genuine Biosystem Pvt Ltd.
  • 16.20. High Technology, Inc.
  • 16.21. PZ Cormay S.A.
  • 16.22. QuidelOrtho Corporation
  • 16.23. Randox Laboratories Ltd.
  • 16.24. Siemens Healthineers AG
  • 16.25. Sysmex Asia Pacific Pte Ltd.
  • 16.26. Teco Diagnostics
  • 16.27. Thermo Fisher Scientific Inc.
  • 16.28. YD Diagnostics

LIST OF FIGURES

  • FIGURE 1. GLOBAL URINALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL URINALYSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL URINALYSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL URINALYSIS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL URINALYSIS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL URINALYSIS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL URINALYSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL URINALYSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL URINALYSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES URINALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA URINALYSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL URINALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL URINALYSIS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL URINALYSIS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL URINALYSIS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL URINALYSIS MARKET SIZE, BY DIPSTICKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL URINALYSIS MARKET SIZE, BY DIPSTICKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL URINALYSIS MARKET SIZE, BY DIPSTICKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL URINALYSIS MARKET SIZE, BY DISPOSABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL URINALYSIS MARKET SIZE, BY DISPOSABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL URINALYSIS MARKET SIZE, BY DISPOSABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL URINALYSIS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL URINALYSIS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL URINALYSIS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL URINALYSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL URINALYSIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL URINALYSIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL URINALYSIS MARKET SIZE, BY FLOWCYTOMETRIC URINE ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL URINALYSIS MARKET SIZE, BY FLOWCYTOMETRIC URINE ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL URINALYSIS MARKET SIZE, BY FLOWCYTOMETRIC URINE ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL URINALYSIS MARKET SIZE, BY MICROSCOPIC URINE ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL URINALYSIS MARKET SIZE, BY MICROSCOPIC URINE ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL URINALYSIS MARKET SIZE, BY MICROSCOPIC URINE ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL URINALYSIS MARKET SIZE, BY SEMI-AUTOMATED URINE SEDIMENT ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL URINALYSIS MARKET SIZE, BY SEMI-AUTOMATED URINE SEDIMENT ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL URINALYSIS MARKET SIZE, BY SEMI-AUTOMATED URINE SEDIMENT ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL URINALYSIS MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL URINALYSIS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL URINALYSIS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL URINALYSIS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL URINALYSIS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL URINALYSIS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL URINALYSIS MARKET SIZE, BY KIDNEY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL URINALYSIS MARKET SIZE, BY KIDNEY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL URINALYSIS MARKET SIZE, BY KIDNEY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL URINALYSIS MARKET SIZE, BY LIVER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL URINALYSIS MARKET SIZE, BY LIVER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL URINALYSIS MARKET SIZE, BY LIVER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL URINALYSIS MARKET SIZE, BY UTI SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL URINALYSIS MARKET SIZE, BY UTI SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL URINALYSIS MARKET SIZE, BY UTI SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL URINALYSIS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL URINALYSIS MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL URINALYSIS MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL URINALYSIS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL URINALYSIS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL URINALYSIS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL URINALYSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL URINALYSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL URINALYSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL URINALYSIS MARKET SIZE, BY RESEARCH & ACADEMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL URINALYSIS MARKET SIZE, BY RESEARCH & ACADEMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL URINALYSIS MARKET SIZE, BY RESEARCH & ACADEMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL URINALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS URINALYSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL URINALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 145. GCC URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 146. GCC URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 148. GCC URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. GCC URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 169. G7 URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 170. G7 URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 172. G7 URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 173. G7 URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 177. NATO URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 178. NATO URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 181. NATO URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. NATO URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES URINALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA URINALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)